CJC-1295 DAC – Long-Acting GHRH Research Peptide

CJC-1295 DAC Peptide Research

CJC-1295 DAC is a synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH) investigated in laboratory, preclinical, and clinical research involving growth hormone signaling, IGF-1 pathways, peptide pharmacology, and endocrine biology.

The DAC component refers to a drug-affinity complex designed to promote binding with endogenous albumin after administration. This modification gives CJC-1295 DAC a substantially longer circulating half-life than shorter-acting GHRH analogues. FDA research materials describe CJC-1295 DAC as more stable and longer-acting than GHRH(1-29).

Research Material for Laboratory Applications

CJC-1295 DAC is intended for qualified laboratory and analytical research involving peptide chemistry, GHRH signaling, receptor pharmacology, endocrine pathways, and growth hormone biology.

Researchers can investigate CJC-1295 DAC under controlled experimental conditions to examine peptide stability, pharmacokinetic characteristics, receptor-mediated signaling, and effects on GH and IGF-1 pathways.

The product quantity listed on a research product should be understood as the amount of research material supplied and should not be interpreted as a human dosage or administration recommendation.

Growth Hormone Research

CJC-1295 DAC has been investigated for its ability to stimulate growth hormone secretion. In a randomized, placebo-controlled study involving healthy adults, administration of CJC-1295 produced dose-dependent increases in circulating GH and IGF-1 concentrations, with effects persisting for several days after a single administration. The researchers estimated a half-life of approximately 5.8–8.1 days.

These findings make CJC-1295 DAC a useful research compound for investigating prolonged GHRH stimulation and the relationship between GHRH signaling, growth hormone secretion, and IGF-1 production.

DAC Modification and Pharmacokinetics

One of the defining characteristics of CJC-1295 DAC is its albumin-binding modification. Research describes CJC-1295 as a synthetic GHRH analogue that can bind to endogenous albumin, extending its residence time in the circulation.

FDA materials specifically distinguish CJC-1295 DAC from other CJC-1295 forms and describe the DAC modification as contributing to increased stability and a longer half-life.

This makes the DAC form particularly relevant to research examining long-acting peptide design, pharmacokinetics, and sustained receptor signaling.

GH and IGF-1 Signaling Research

Experimental research has examined the relationship between CJC-1295 administration and the GH/IGF-1 axis. Human research found increased GH and IGF-1 concentrations following CJC-1295 administration while maintaining pulsatile GH secretion.

Researchers may therefore use CJC-1295 DAC as a model compound when studying endocrine signaling, GHRH receptor pathways, GH secretion, and downstream IGF-1 responses.

Laboratory Research Applications

CJC-1295 DAC may be relevant to qualified research involving:

• GHRH signaling
• Growth hormone research
• IGF-1 pathway research
• Peptide-receptor interactions
• Long-acting peptide design
• Pharmacokinetic research
• Peptide stability studies
• Endocrine signaling
• Molecular pharmacology
• Analytical peptide characterization

Research results can vary depending on the experimental model, peptide formulation, concentration, analytical method, and study conditions.

CJC-1295 DAC vs. CJC-1295 Without DAC

CJC-1295 DAC sh